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Editorial
The Search for More Reliable Estimated GFR Biomarkers
Related Article, p. 40

I

n this issue of AJKD, Inker et al1 explore the role of
the unconventional endogenous ﬁltration markers,
b-trace protein (BTP) and b2-microglobulin (B2M),
for estimating glomerular ﬁltration rate (GFR).
Because of challenges associated with precise measurements of kidney function in clinical practice and
clinical research, more accurate estimation of GFR
may have important implications in medicine.
Kidney function cannot be measured directly.
Accordingly, GFR, which can be measured using
exogenous ﬁltration markers and can be estimated
using endogenous ﬁltration markers, is the most
widely accepted surrogate marker of kidney function.2 A GFR marker must have a stable concentration
in plasma and must be physiologically inert, must be
freely ﬁltered by the glomerulus, and must not be
secreted, reabsorbed, synthesized, or metabolized by
the kidney, so that the amount ﬁltered equals the
amount excreted in urine.3 The gold standard for GFR
measurement is inulin clearance, a method introduced
by Homer Smith in 1933.4 Today, methods using
iohexol, iothalamate, or EDTA have replaced inulin
clearance, but all these are cumbersome, are invasive,
have considerable imprecision, and involve exposure
to exogenous substances, making them somewhat
impractical.2
Reﬂecting these limitations, many endogenous
biomarkers of GFR have been proposed over the
centuries. The year 1773 saw the ﬁrst attempts to
quantify kidney function with the quantitation of
serum urea.5 A century and a half later, Moller
introduced the concept of urea clearance as a measure
of kidney function, deﬁning clearance as “the volume
of blood that a one minute’s excretion of urine sufﬁces to completely clear of urea.”6-9 Meanwhile, the
history of creatinine dates back to 1847, when Liebig10 heated creatine with mineral acids and named
the resulting substance creatinine. In 1929, Rehberg11
suggested that creatinine was ﬁltered through
glomeruli and concentrated in tubules, and 6 years
later, Shannon12 showed that creatinine clearance
values approximate the clearance of inulin. The next
year, Popper and Mandel13 proposed the use of serum
creatinine for GFR estimation. Two decades later,
another marker of GFR was proposed, serum indican
(indoxyl sulfate),14 a protein-bound solute generated
from the metabolism of tryptophan, phenylalanine,
and tyrosine in the colon.15
Timed urine collection proved to be very unreliable,
yielding a very high coefﬁcient of variation (29%)
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even when using rigidly controlled conditions.16
Because of intraindividual day-to-day ﬂuctuations,
creatinine excretion of an accurately collected 24-hour
urine sample would have to be measured for several
days, rendering this approach impractical.16 As a
result, 24-hour biomarker clearance was largely
abandoned for single plasma concentrations, and
serum creatinine has remained the most widely used
marker for GFR estimation despite its many shortcomings.2 Although more precise measurement of
serum creatinine through widespread implementation
of isotope-dilution mass spectrometry traceability in
clinical chemistry laboratories has reduced some of the
analytical problems,17,18 considerable issues remain
related to the properties of creatinine, including variability in muscle mass, dietary intake, creatinine production, and nonrenal elimination, especially in select
populations such as individuals with atypically high or
low muscle mass19 and children.2,20
Additional options include other endogenous
small-molecular-weight proteins. Jung and coworkers
were the ﬁrst to propose small-molecular-mass proteins as markers of GFR because typically they are
essentially freely ﬁltered through a healthy glomerular
membrane.21-23 Of these, cystatin C24 appears to be
the best marker to date, especially since Grubb et al25
introduced a certiﬁed international standardized
reference material for cystatin C.
However, although cystatin C has been demonstrated to be independent of muscle mass and clearly
superior in its ability to detect a decrease in GFR in
the so-called “creatinine-blind range,”26 it subsequently became clear that combining 2 (or more)
endogenous markers improves the accuracy of GFR
estimation equations.27-29 This is not surprising
because cystatin C levels can be affected by patient
characteristics, such as inﬂammation, hyperthyroidism, high-dose steroids, and even triglycerides.24,30 In
reality, there probably is no individual protein that has
a totally constant production unaffected by changes in
systemic metabolism and systemic inﬂammatory reactions. Today, the CKiD (Chronic Kidney Disease in
Children)31 and CKD-EPI (Chronic Kidney Disease
Epidemiology Collaboration)29 equations are the
most established formulas for the estimation of GFR
in children and adults, respectively. Combining 2
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well-established markers of estimated GFR (eGFR)
such as serum creatinine and cystatin C, with their
different strengths and challenges, should be superior
to the estimation of GFR using 1 biomarker alone.
However, it should be noted that each formula works
best in the population type and within the GFR range
in which it was generated.32
In the past, other small-molecular-weight proteins
have also been proposed as ﬁltration markers, most
notably BTP and B2M.33,34 Some doubts were cast
upon B2M when viewed in isolation,33 reﬂecting the
inﬂuence of acute-phase reactions on its levels, as was
demonstrated in patients with lupus35; notably
though, it is used at times as a dialysis adequacy
marker. BTP appears to be similarly promising as
cystatin C, with certain advantages in special populations such as pregnant women and neonates.36 The
advantages of BTP as a marker of GFR are discussed
in detail in our recent review.36
In this context, Inker et al1 evaluated the utility of
BTP and B2M to estimate GFR. Using data from
3,551 participants in 3 large populations with CKD,
they developed and validated a robust GFR estimating
equation using these biomarkers and commonly
available clinical characteristics. They carefully
adjusted for covariates such as sex, ethnicity, and age.
For BTP alone, sex and age remained signiﬁcant inﬂuences. The impact of sex conﬁrms our previous
ﬁndings.37,38 For B2M, there was no effect of sex,
and the equation based on BTP and B2M was free of
signiﬁcant bias. Not unexpectedly, this study demonstrates that age, sex, and race are less inﬂuential for
both these small-molecular-weight proteins in comparison to creatinine, but not cystatin C. Most
importantly, the authors demonstrated that the coefﬁcient of variation of B2M for sex was smaller than
that of cystatin C, which is probably due to the
increased fat mass of women because adipocytes are
the only nucleated cells in the body that do not produce cystatin C.24 The authors then combined B2M
and BTP and the resultant formula had similar accuracy to the CKD-EPI creatinine–cystatin C equation.
Inker et al conclude that BTP and B2M are less
inﬂuenced by age, sex, and race than creatinine and
less inﬂuenced by race than cystatin C. Their new
equation appears to provide a methodological
advantage, although they clearly point out the limitations of this post hoc analysis and mandate further
prospective evaluations before clinical use is
recommended.
This is good advice in view of the limited availability of BTP assays. Currently, BTP measurement is
generally used for the detection of cerebrospinal ﬂuid
leakage,36 and only a few laboratories routinely offer
serum BTP for the assessment of eGFR.36,37,39 In
addition, it is likely that each biomarker will have
6

some populations in which it is particularly well or
poorly suited. Both BTM and B2M appear to have
some advantages over serum creatinine for GFR
estimation, but systemic inﬂammation and other factors clearly have some inﬂuence on the production of
small-molecular-weight proteins, making the utility of
these novel biomarkers less certain in people with
acute and chronic systemic inﬂammatory states. The
question is, how many markers should we combine?
Clearly, a combination of all 4 markers may produce
slightly higher agreement with measured GFR, but the
clinical utility of equations containing too many
components is limited.
It should not be forgotten that the GFR measurement method used in the 3 large patient cohorts in the
Inker et al study under discussion has some plasma
protein-binding tendencies that affect its accuracy in
comparison to inulin.2 Iohexol may currently be the
second-best GFR method after inulin. In this context,
Seegmiller et al40 recently assessed the discordance
between iothalamate and iohexol urinary clearances
(the latter were used by Inker et al). Although they did
not measure inulin clearance, they showed that that
the mean proportional ratio of iohexol to iothalamate
clearance was 0.85 (95% conﬁdence interval, 0.830.88) across the range of GFRs, indicating that GFR
measured using iohexol clearance is lower than GFR
measured using iothalamate clearance. These relatively small but signiﬁcant biases were opposite to
each other, which may reduce the impact on the
“gold-standard” method used by Inker et al.
Ultimately, to design the best possible estimating
strategies, the community should unite to design
collaborative worldwide prospective studies using
inulin as the gold standard for clearance measured
with tandem mass spectrometry to reduce the imprecision of the inulin measurement, using only biomarkers with certiﬁed international standardized
reference materials (it is important to note that these
are needed for B2M and BTP), and combining these
studies with proteomics and metabolomics to identify
additional internal biomarkers of GFR that perhaps
are less inﬂuenced by acute-phase reactions. Combinations other than cystatin C and creatinine may be
useful, especially in select populations. The cost difference of BTP and B2M over cystatin C and creatinine may render this new approach impractical, but
with more widespread use, assay costs will come
down. A more cost-efﬁcient approach may be the
determination of multiple serum proteins by mass
spectrometry. Taking a high-level view, one should
also question the emphasis on GFR when assessing
kidney function. Tubular function is responsible for a
large proportion of kidney function, especially with
regard to drug clearance, and disturbance in GFR and
tubular function do not necessarily change plasma
Am J Kidney Dis. 2016;67(1):5-8
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proteins in parallel. Nonetheless, the study by Inker
et al forms a very important contribution to the search
for the best biomarker of eGFR.
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